Central Nervous System (CNS) Lymphoma Global Market Report 2025

The central nervous system (CNS) lymphoma market size has grown strongly in recent years. It will grow from $1.44 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 7%. The growth during the historical period can be attributed to factors such as increased awareness and diagnosis, a rising incidence of lymphoma, a growing number of clinical trials, increased funding for cancer research, and a greater use of biomarkers for targeted treatments.

The central nervous system (CNS) lymphoma market size is expected to see strong growth in the next few years. It will grow to $1.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be attributed to factors such as the growing adoption of immunotherapy, an increasing focus on targeted treatments, a rising prevalence of CNS lymphoma, improved patient access to healthcare, and government support and initiatives. Key trends during this period include the integration of artificial intelligence in diagnostics, the development of next-generation monoclonal antibodies, a shift toward less invasive treatments, advancements in precision medicine, and innovations in diagnostic technologies.

The increasing incidence of psychological disorders is expected to significantly drive the growth of the central nervous system (CNS) lymphoma market. Psychological disorders, which affect thoughts, emotions, and behaviors, are influenced by factors such as stress, social isolation, economic pressures, genetics, substance abuse, and excessive use of digital technologies. As the prevalence of these disorders rises, it advances neuro-oncology research, which enhances the understanding of brain inflammation, immune system interactions, and the blood-brain barrier. This deeper insight contributes to the development of better treatments for both cancer and mental health conditions. For instance, the National Alliance on Mental Illness reported in 2024 that nearly 600,000 hospitalizations in the U.S. each year are due to psychosis spectrum and mood disorders among individuals aged 18-44. Therefore, the rising incidence of psychological disorders plays a role in propelling growth in the CNS lymphoma market.

The increasing prevalence of neurological disorders is another factor expected to boost the central nervous system (CNS) lymphoma market. Neurological disorders, which affect the brain, spinal cord, and nerves, are becoming more common due to factors such as genetics, infections, trauma, toxins, autoimmune responses, and degenerative processes. CNS lymphoma research contributes significantly to advancing diagnostics and treatments for neurological disorders by improving understanding of brain function, immune response, and neuroinflammation. For example, in April 2022, the European Brain Council reported that over 600 neurological diseases and nearly 300 psychiatric conditions impact millions of people worldwide, including 65 million with epilepsy. Additionally, projections indicate that the number of people in Europe affected by dementia will rise from 10.5 million in 2022 to 18.7 million by 2050. As such, the growing prevalence of neurological disorders is expected to fuel demand and drive the growth of the CNS lymphoma market.

In March 2023, ONO Pharma Inc. received orphan drug designation from the U.S. Food and Drug Administration (FDA) for tirabrutinib (ONO-4059) as a treatment for PCNSL. Currently under investigation in the phase 2 PROSPECT study, tirabrutinib targets critical pathways involved in B-cell proliferation and survival, offering new potential treatment options for B-cell malignancies such as primary CNS lymphoma. This highlights the ongoing efforts to develop innovative therapies to address CNS lymphoma and related neurological conditions.

Major players in the central nervous system (CNS) lymphoma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Incyte Corporation, ONO PHARMA USA Inc., Kazia Therapeutics Limited, Simcere Pharmaceutical Group Limited, Karyopharm Therapeutics Inc., Nurix Therapeutics Inc., CNS Pharmaceuticals Inc., JW Therapeutics, PentixaPharm Pty Ltd, Cellectar Biosciences Inc.

North America was the largest region in the central nervous system (CNS) lymphoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in central nervous system (CNS) lymphoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the central nervous system (CNS) lymphoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Central nervous system (CNS) lymphoma is a rare and aggressive form of lymphoma that originates in the brain or spinal cord. The primary goal of treatment is to target and shrink cancerous cells in the CNS, alleviate symptoms, and improve survival rates through a combination of medications, targeted therapies, and focused high-energy treatments.

The main drugs in the central nervous system (CNS) lymphoma market include monoclonal antibodies, chemotherapeutic agents, and corticosteroids. Monoclonal antibodies are laboratory-created proteins that replicate the immune system’s ability to identify and neutralize specific targets, such as cancer cells, viruses, or inflammatory molecules. These treatments are administered through various methods, including chemotherapy, radiation therapy, steroid therapy, and targeted therapy. The market also serves a range of applications, including hospitals, clinics, ambulatory surgical services, and other healthcare settings.

The central nervous system (CNS) lymphoma market research report is one of a series of new reports that provides central nervous system (CNS) lymphoma market statistics, including the central nervous system (CNS) lymphoma industry global market size, regional shares, competitors with the central nervous system (CNS) lymphoma market share, detailed central nervous system (CNS) lymphoma market segments, market trends, and opportunities, and any further data you may need to thrive in the central nervous system (CNS) lymphoma industry. This central nervous system (CNS) lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The central nervous system (CNS) lymphoma market consists of revenues earned by entities by providing services such as diagnostic service, therapy services, and supportive and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The central nervous system (CNS) lymphoma market also includes sales of drugs, therapy equipment, supportive therapies, and surgical instruments & tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.